REGENXBIO Inc. today announced positive data from long-term follow-up studies of investigational surabgene lomparvovec ...
9h
4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population
After a single intravitreal dose of 4D-150, visual acuity and anatomic control was maintained with consistent and durable treatment burden ...
Diabetic retinopathy severity and the risk of vision-threatening complications decreased significantly in patients treated ...
MedPage Today on MSN
New Agents for AMD Preserve Vision, Dramatically Reduce Treatment Burden
Bispecific antibody fares well against faricimab, two gene therapies extend treatment inte ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results